Skip to main content
. 2022 Feb 10;12:804113. doi: 10.3389/fneur.2021.804113

Figure 1.

Figure 1

Relative levels of secreted IL-6 and IL-21 in the supernatants of AChR-stimulated PBMCs. (A) Treatment schematic of EAMG model (grade 2) with HDAC inhibitors (HDAC-i). (B) Relative IL-6 levels in the supernatant upon stimulation of PBMCs with AChR at the indicated post treatment time points. (C) Relative IL-21 levels in the supernatant of AChR-stimulated (26 h) PBMCs from EAMG mice treated or not with HDAC-i. (D) Relative levels of IL-6 secreted from PBMCs stimulated for 26 h with specific (AChR) or nonspecific stimulus (PMA/ionomycin) or no stimulus (PBS-only). PBMCs were isolated 72 h later from untreated EAMG mice or EAMG mice treated with HDAC-i (post 3rd treatment). Each dot represents mean +/- standard deviation; readings are from triplicate microplate wells belonging to the same group of pooled supernatant samples. CFA (n = 3) and each EAMG (n = 5 per group). ***P < 0.001, ANOVA. The experiment is representative of three similar experiments.